Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients
Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients
In order to obtain information on a wider range of doses of GW642444 (a possible new
 medication to treat asthma) than has been previously examined in asthmatic patients, this
 current study will be conducted at doses of 25 100 and 400 mcg of GW642444 and will be
 compared with salmeterol (50 mcg twice daily). This study will be conducted in a similar
 manner to a study that has already been completed (study number B2C101762) which examined
 repeat doses of 50, 100 and 200 mcg of GW642444. The data obtained will compliment the data
 from study B2C101762 and will provide confidence (or not) that the desired bronchodilation
 can be achieved and maintained without undesirable side effects.
Inclusion criteria:

 -  Subjects with a documented history of persistent asthma.

 -  Current non-smokers.

 -  Clinically stable persistent asthma FEV1 between 60 and 90% of predicted values.

 -  Inhaled corticosteroid therapy at a total daily dose between 200-500mcg of fluticasone
 or equivalent.

 Exclusion criteria:

 -  Subjects with significant past or present disease which which may affect their safety.

 -  Upper or lower respiratory tract infection within 4 weeks of screening.

 -  History of life threatening asthma, or asthma requiring treatment with oral
 corticosteroids within 3 months of study.

 -  Patients taking doses of inhaled corticosteroid >500mcg/day and patients who have
 changed therapy within 8 weeks of the study.

 -  Patients weighing less than 50kg.